Home
Issues
2022
April 2022 Vol 12, No 2
March 2022 Vol 12 Special Feature
February 2022 Vol 12, No 1
2021
December 2021 Vol 11, No 6
October 2021 Vol 11, No 5
August 2021 Vol 11, No 4
June 2021 Vol 11, No 3
April 2021 Vol 11, No 2
March 2021 Vol 11 Special Feature
February 2021 Vol 11, No 1
2020
December 2020, Vol 10, No 6
October 2020, Vol 10, No 5
August 2020, Vol 10, No 4
June 2020, Vol 10, No 3
April 2020 Vol 10, No 2
February 2020 Vol 10, No 1
Issue Archive
Online First
Special Issues
Supplements
Guide to New FDA Approvals
2021 Year in Review
Multiple Myeloma
Advances in Dual Immunotherapy Cancer Treatments
Renal-Cell Carcinoma
Breast Cancer
Ovarian Cancer
Biosimilars
Non–Small-Cell Lung Cancer
Gastrointestinal Cancer
Categories
Conference Correspondent
Dual IO 2021 Year in Review
AACR & ASCO 2021 - Midyear Review
ASCO 2021 Breast Cancer Highlights
ASCO Highlights
ASH Highlights
ESMO Highlights
SABCS Highlights
Web Exclusives
All Web Exclusives
Interview with the Innovators
FDA Approvals
Videos
Press Releases
Lung Cancer Monthly Minutes
Gastrointestinal Cancer Monthly Minutes
Melanoma Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Peer Review Application
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Advertise
Subscribe
Sign Up Now!
To sign up for our newsletter or print publications, please enter your contact information below.
First Name
*
Last Name
*
Email Address
*
Email Address (Verify)
*
JHOP Print Edition
We will request your mailing address on the next page.
JHOP E-Newsletters & Communications
TOP Print Edition
We will request your mailing address on the next page.
TOP E-Newsletters & Communications
I have reviewed and consent to the terms of
JHOP
's
Privacy Policy
, and
JHOP
has my permission to retain my information in its database, and to forward pertinent communications to me.
Home
Issues
2022
April 2022 Vol 12, No 2
March 2022 Vol 12 Special Feature
February 2022 Vol 12, No 1
2021
December 2021 Vol 11, No 6
October 2021 Vol 11, No 5
August 2021 Vol 11, No 4
June 2021 Vol 11, No 3
April 2021 Vol 11, No 2
March 2021 Vol 11 Special Feature
February 2021 Vol 11, No 1
2020
December 2020, Vol 10, No 6
October 2020, Vol 10, No 5
August 2020, Vol 10, No 4
June 2020, Vol 10, No 3
April 2020 Vol 10, No 2
February 2020 Vol 10, No 1
Issue Archive
Online First
Special Issues
Supplements
Guide to New FDA Approvals
2021 Year in Review
Multiple Myeloma
Advances in Dual Immunotherapy Cancer Treatments
Renal-Cell Carcinoma
Breast Cancer
Ovarian Cancer
Biosimilars
Non–Small-Cell Lung Cancer
Gastrointestinal Cancer
Categories
Conference Correspondent
Dual IO 2021 Year in Review
AACR & ASCO 2021 - Midyear Review
ASCO 2021 Breast Cancer Highlights
ASCO Highlights
ASH Highlights
ESMO Highlights
SABCS Highlights
Web Exclusives
All Web Exclusives
Interview with the Innovators
FDA Approvals
Videos
Press Releases
Lung Cancer Monthly Minutes
Gastrointestinal Cancer Monthly Minutes
Melanoma Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Peer Review Application
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Advertise
Meeting Highlights
Meeting Highlights
ESMO Highlights
Results from the GEICO1601-ROLANDO Phase 2 Trial Evaluating Combination of Olaparib and PLD in Platinum-Resistant Ovarian Cancer
Read More
Meeting Highlights
ESMO Highlights
Results of 5-Year Follow-Up of Maintenance Olaparib in Patients with Newly Diagnosed, Advanced Ovarian Cancer
Read More
Meeting Highlights
ESMO Highlights
Olaparib + Durvalumab and Bevacizumab: Initial Results in Patients with Non-Germline BRCA-Mutated Platinum-Sensitive Relapsed Ovarian Cancer
Read More
Meeting Highlights
ESMO Highlights
Phase 2 Trial of Olvi-Vec in Heavily Pretreated Platinum-Resistant/Refractory Ovarian Cancer
Read More
Meeting Highlights
ESMO Highlights
Efficacy and Safety of Niraparib in Older Patients with Advanced Ovarian Cancer from PRIMA/ENGOT-OV26/GOG-3012
Read More
Meeting Highlights
ESMO Highlights
Olaparib Maintenance Therapy in Clinical Practice: Quality-of-Life Interim Results of the C-PATROL Study in Ovarian Cancer
Read More
Meeting Highlights
ESMO Highlights
Response to Olaparib Monotherapy in Relapsed Ovarian Cancer by HRR Gene Mutational Status and HRD Scarring Analysis
Read More
Meeting Highlights
ESMO Highlights
Timing of Adverse Events During Maintenance Treatment with Rucaparib for Recurrent Ovarian Cancer in Phase 3 Study
Read More
Meeting Highlights
ESMO Highlights
Efficacy and Safety of Front-Line Veliparib and Paclitaxel Weekly versus Every 3 Weeks in the VELIA Study
Read More
Meeting Highlights
AACR Highlights
Atezolizumab, Vemurafenib, and Cobimetinib Triplet Therapy Improves PFS in BRAF-Positive Melanoma
Phoebe Starr
Read More
4
5
6
7
8
9
10
Page 7 of 16
Results 61 - 70 of 157
Privacy policy
Terms of Use
Home
About
Subscribe
Advertise
Contact Us
Copyright © Green Hill Healthcare Communications, LLC. All rights reserved.
